Evolva announces API partnership with US firm

摘要

Swiss biotech firm, Evolva, has entered into an agreement with a private US biotech venture to develop new production routes for a family of existing active pharmaceutical ingredients (APIs). Evolva will be responsible for the development of the produc- tion routes, while its unnamed partner will be responsible for the registration and commercialisation of the resulting products. The collaboration follows Evolva's strategy of monetising applications outside its focus areas with partners.